Olema Pharmaceuticals, Inc.
OLMA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001750284
In the last 90 days, Olema Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 1 sale; 185 institutions reported holding it in 13F filings for Q2 2026, worth $1.28B in total; Duquesne Family Office is the only superinvestor holding it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Olema Pharmaceuticals, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 1 filing
- 1 insider, $291.2K in total
- Insiders trading
- 1
- Net value
- −$291.2K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Olema Pharmaceuticals, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| O'Byrne Jason | CHIEF FINANCIAL OFFICER | – | Sep 2, 2026 | 1 |
| Harmon Cyrus | Director | 702,770 | Jul 27, 2026 | 5 |
| Biotechnology Value Fund L P | Director, Other: See Explanation of Responses | 347,970 | Jun 23, 2026 | 1 |
| BVF Partners L P | Director, Other: See Explanation of Responses | 347,970 | Jun 23, 2026 | 1 |
| BVF Inc | Director, Other: See Explanation of Responses | 347,970 | Jun 23, 2026 | 1 |
| Biotechnology Value Fund II LP | Director, Other: See Explanation of Responses | 347,970 | Jun 23, 2026 | 1 |
| Lampert Mark N | Director, Other: See Explanation of Responses | 347,970 | Jun 23, 2026 | 1 |
| Biotechnology Value Trading Fund OS LP | Director, Other: See Explanation of Responses | 347,970 | Jun 23, 2026 | 1 |
| BVF Partners OS Ltd. | Director, Other: See Explanation of Responses | 347,970 | Jun 23, 2026 | 1 |
| BVF I GP LLC | Director, Other: See Explanation of Responses | 347,970 | Jun 23, 2026 | 1 |
| BVF II GP LLC | Director, Other: See Explanation of Responses | 347,970 | Jun 23, 2026 | 1 |
| BVF GP Holdings LLC | Director, Other: See Explanation of Responses | 347,970 | Jun 23, 2026 | 1 |
| Rappaport Andrew | Director | 0 | Jun 23, 2026 | 2 |
| Butitta Cynthia M | Director | – | Jun 23, 2026 | 1 |
| Clark Ian T | Director | 0 | Jun 23, 2026 | 2 |
| Garland J. Scott | Director | – | Jun 23, 2026 | 1 |
| Horning Sandra | Director | – | Jun 23, 2026 | 1 |
| Graham G. Walmsley | Director | 700,761Indirect | Jun 23, 2026 | 1 |
| Larson Yi | Director | – | Jun 23, 2026 | 1 |
| Hrustanovic Gorjan | Director | – | Jun 23, 2026 | 1 |
| Raman Prakash | Director | – | Jun 23, 2026 | 2 |
| Mitchell Shawnte | CHIEF LEGAL OFFICER | 0 | Mar 5, 2026 | 2 |
| Austin Sasha Lu | VP of Finance and Controller | 16,188 | Feb 17, 2026 | 1 |
| Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | 542,761 | Feb 4, 2026 | 3 |
| Bohen Sean | PRESIDENT AND CEO | 237,650 | Feb 4, 2026 | 2 |
| Zojwalla Naseem | CHIEF MEDICAL OFFICER | 4,488 | Feb 4, 2026 | 2 |
| Kovacs Shane William Charles | CH. OPERATING & FINANCIAL OFF. | 139,727 | Jan 15, 2026 | 3 |
| Bain Capital Life Sciences Investors, LLC | 10% Owner | 4,300,000Indirect | Jan 13, 2025 | 0 |
| Bain Capital Life Sciences IV General Partner, LLC | 10% Owner | 4,300,000Indirect | Jan 13, 2025 | 0 |
| Bain Capital Life Sciences Fund IV, L.P. | 10% Owner | 4,300,000Indirect | Jan 13, 2025 | 0 |
| Bain Capital Life Sciences Opportunities IV, L.P. | 10% Owner | 4,300,000Indirect | Jan 13, 2025 | 0 |
| Bain Capital Life Sciences Opportunities IV GP, LLC | 10% Owner | 4,300,000Indirect | Jan 13, 2025 | 0 |
| Paradigm BioCapital International Fund Ltd. | 10% Owner | 783,118Indirect | Aug 5, 2024 | 0 |
| Paradigm Biocapital Advisors LP | 10% Owner | 783,118Indirect | Aug 5, 2024 | 0 |
| Paradigm BioCapital Advisors GP LLC | 10% Owner | 783,118Indirect | Aug 5, 2024 | 0 |
| Asefaw Senai | 10% Owner | 783,118Indirect | Aug 5, 2024 | 0 |
| Moriarty John B | EVP, Ch. Legal Officer & Sec. | – | Feb 2, 2023 | 0 |
| Horn Kinney | Chief Business Officer | 2,458 | Feb 2, 2023 | 0 |
| Kushner Peter J. | CHIEF SCIENTIFIC OFFICER | – | Feb 3, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 31, 2024 (view filing) | Jul 29-30 | 2 days | Harmon CyrusDirector | SSale | −5.00K | $15.57 | −$77.9K | −0.7%751.3K after | 2 lots10b5-1 |
| Aug 5, 2024 (view filing)4:30 PM ET | Aug 1 | 4 days | Paradigm BioCapital International Fund Ltd. and 3 others10% Owner | SSaleCommon Stock, par value $0.0001 per share | −2.40M | $14.92 | −$35.8M | −75.4%783.1K after | 2 lots |
| Nov 26, 2024 (view filing) | Jun 4 | 175 days | Graham G. WalmsleyDirector | SSale | −1.18M | $14.85 | −$17.4M | −62.4%708.1K after | Amended2 lots |
| Dec 11, 2024 (view filing) | Dec 10-11 | 1 day | Bohen SeanPRESIDENT AND CEO | SSale | −109.5K | $9.01 | −$986.4K | −31.2%241.7K after | 3 lots |
| Dec 11, 2024 (view filing) | Dec 10-11 | 1 day | Kovacs Shane William CharlesCH. OPERATING & FINANCIAL OFF. | SSale | −35.2K | $9.01 | −$316.7K | −6.1%543.5K after | 3 lots |
| Dec 11, 2024 (view filing) | Dec 10-11 | 1 day | Zojwalla NaseemCHIEF MEDICAL OFFICER | SSale | −27.8K | $9.01 | −$250.5K | −19.4%115.5K after | 3 lots |
| Dec 11, 2024 (view filing) | Dec 10-11 | 1 day | Myles David C.CH. DISCOV. & NON-CLIN DEV OFF | SSale | −26.1K | $9.01 | −$234.9K | −4.2%598.3K after | 3 lots |
| Dec 11, 2024 (view filing) | Dec 10-11 | 1 day | Harmon CyrusDirector | SSale | −16.4K | $9.03 | −$148.0K | −2.1%764.1K after | 3 lots |
| Dec 18, 2024 (view filing) | Dec 13 | 5 days | Graham G. WalmsleyDirector | SSale | −700.8K | $6.75 | −$4.73M | −100.0%0 after | From original |
| Dec 18, 2024 (view filing) | Dec 13 | 5 days | Graham G. WalmsleyDirector | PPurchase | +700.8K | $6.75 | +$4.73M | New position700.8K after | From original |
| Jan 13, 2025 (view filing)4:34 PM ET | Jan 8 | 5 days | Bain Capital Life Sciences Investors, LLC and 4 others10% Owner | PPurchase | +300.0K | $5.76 | +$1.73M | +4.0%7.80M after | |
| Sep 18, 2025 (view filing) | Sep 16-18 | 2 days | Harmon CyrusDirector | SSale | −20.0K | $8.19 | −$163.7K | −2.6%744.1K after | 2 lots |
| Sep 18, 2025 (view filing) | Sep 16-18 | 2 days | Harmon CyrusDirector | SSale | −5.00K | $8.23 | −$41.1K | −4.1%117.0K after | 2 lots |
| Dec 23, 2025 (view filing) | Dec 19 | 4 days | Clark Ian TDirector | SSale | −264.8K | $29.73 | −$7.87M | −100.0%0 after | 3 lots |
| Dec 23, 2025 (view filing) | Dec 19 | 4 days | Myles David C.CH. DISCOV. & NON-CLIN DEV OFF | SSale | −51.0K | $30.46 | −$1.55M | −8.5%551.9K after | 3 lots |
| Dec 23, 2025 (view filing) | Dec 19-23 | 4 days | Zojwalla NaseemChief Medical Officer | SSale | −269.5K | $27.94 | −$7.53M | −98.4%4.49K after | 4 lots |
| Dec 29, 2025 (view filing) | Dec 22 | 7 days | Harmon CyrusDirector | SSale | −2.88K | $28.53 | −$82.2K | −0.4%741.3K after | |
| Jan 14, 2026 (view filing) | Jan 12 | 2 days | Myles David C.CH. DISCOV. & NON-CLIN DEV OFF | SSale | −10.0K | $28.34 | −$283.4K | −6.5%144.8K after | |
| Jan 14, 2026 (view filing) | Jan 13-14 | 1 day | Myles David C.CH. DISCOV. & NON-CLIN DEV OFF | SSale | −100.0K | $28.24 | −$2.82M | −15.6%542.8K after | 4 lots |
| Jan 15, 2026 (view filing) | Jan 13-15 | 2 days | Kovacs Shane William CharlesCH. OPERATING & FINANCIAL OFF. | SSale | −103.8K | $28.70 | −$2.98M | −42.6%139.7K after | 2 lots |
| Jan 16, 2026 (view filing) | Jan 14 | 2 days | Harmon CyrusDirector | SSale | −3.49K | $29.12 | −$101.6K | −0.5%737.8K after | |
| Jan 21, 2026 (view filing) | Jan 20 | 1 day | Harmon CyrusDirector | SSale | −10.0K | $26.88 | −$268.8K | −1.4%727.8K after | |
| Mar 5, 2026 (view filing) | Mar 3-4 | 2 days | Mitchell ShawnteCHIEF LEGAL OFFICER | SSale | −39.8K | $23.78 | −$945.7K | −99.4%233 after | 2 lots |
| Mar 5, 2026 (view filing) | Mar 4 | 1 day | Mitchell ShawnteCHIEF LEGAL OFFICER | SSaleComon Stock | −233 | $24.69 | −$5.75K | −100.0%0 after | |
| Jul 27, 2026 (view filing)7:30 PM ET | Jul 23-24 | 4 days | Harmon CyrusDirector | SSale | −25.0K | $11.65 | −$291.2K | −3.4%702.8K after | 2 lots |